You are here: Home: Audio Program Guide: PCU 1 | 2008 Audio: PCU 1 | 2008
 
 

Go to interview with Oliver Sartor, MD
Go to inteview with Peter T Scardino, MD

 
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Sartor, MD Oliver Sartor, MD
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Trials (Genitourinary)
Dana-Farber Cancer Institute
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Radiation therapy combined with hormonal therapy for patients with high-risk prostate cancer
Track 2 Surgery for patients with high-risk prostate cancer
Track 3 Management of PSA recurrence after prostatectomy
Track 4 Trends toward improvement of prostate cancer mortality
Track 5 Investigating genomic assays in prostate cancer
Track 6 Benefits and toxicities associated with hormonal therapy for patients with PSA recurrence

Track 7 Antiandrogens in the management of prostate cancer
Track 8 Clinical use of androgen deprivation therapy for PSA-only disease
Track 9 Role of PSA doubling time in determining when to initiate therapy for PSA-only disease
Track 10 Clinical use of docetaxel in patients with PSA-only disease and a rapid PSA doubling time
Track 11 Counseling patients about the risks and benefits associated with docetaxel
Track 12 Ongoing clinical trials evaluating docetaxel in early-stage prostate cancer

Track 13 Clinical use of docetaxel in patients with PSA-only, hormone-refractory disease
     
Scardino, MD Peter T Scardino, MD
Chair, Department of Surgery
Head, Prostate Cancer Program
Florence and Theodore Baumritter/
Enid Ancell Chair of Urologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
Track 1 Prognostic significance of molecular markers in prostate cancer
Track 2 Applying systems pathology to prostate cancer
Track 3 Androgen receptor levels in prostate cancer cells
Track 4 Association between higher androgen receptor levels and aggressive prostate cancer
Track 5 Development of a novel antiandrogen, abiraterone
Track 6 Increased androgen receptor levels in hormone-refractory prostate cancer
Track 7 Blocking androgen synthesis with abiraterone
Track 8 Response to androgen deprivation therapy in men with high androgen receptor levels
Track 9 Trials evaluating docetaxel in early-stage prostate cancer
Track 10 Use of chemotherapy for asymptomatic, hormone-refractory disease
Track 11 Need for additional randomized clinical trial data in prostate cancer

Track 12 Consortium of clinical trials sponsored by the Department of Defense
Track 13 Integrating the medical oncologist into the management of prostate cancer
Track 14 Improving accrual to prostate cancer clinical trials
Track 15 Potential role for combining hormonal therapy with immunotherapy for metastatic prostate cancer
Track 16 Robotics in prostate cancer surgery

Track 17 Prostate Cancer Prevention Trial of finasteride